Results 161 to 170 of about 37,235 (219)
Some of the next articles are maybe not open access.
Disease-a-Month, 1994
The leukemias can be divided into acute and chronic varieties, both of which have a myelocytic and lymphocytic type. When untreated, the acute leukemias are associated with a more rapid clinical course than are the chronic leukemias. Paradoxically, to the present time, the acute leukemias have been curable with chemotherapy, whereas the chronic ...
openaire +2 more sources
The leukemias can be divided into acute and chronic varieties, both of which have a myelocytic and lymphocytic type. When untreated, the acute leukemias are associated with a more rapid clinical course than are the chronic leukemias. Paradoxically, to the present time, the acute leukemias have been curable with chemotherapy, whereas the chronic ...
openaire +2 more sources
“Atypical” Leukemias: Preleukemia, Smoldering Leukemia and Hypoplastic Leukemia
1984The term “atypical leukemia” covers a wide range of heterogeneous disorders whose classification has hitherto been controversial. This controversy has arisen from the use of different criteria for the definition of the various entities. The application of morphological criteria has led to the separation of conditions without recognizable leukemic ...
D, Hoelzer, A, Ganser, H, Heimpel
openaire +2 more sources
Leukemia cutis in acute lymphoblastic leukemia
Journal of the American Academy of Dermatology, 1994separating normal epidermis from a diffuse dermal infiltrate of lymphoid blast cells with round and regular nuclei, inconspicuous nucleoli, and scanty, moderately basophilic cytoplasm. Immunophenotype analysis revealed strong positivity for CD 10.The patient wastreated with methotrexate, teniposide, cytosine arabinoside, and local irradiation, and a ...
J F, de Lacerda +5 more
openaire +2 more sources
Current Oncology Reports, 2001
Leukemia is susceptible to immune-mediated therapies such as allogeneic stem-cell transplantation, donor lymphocyte infusion, and interferon. The clinical effectiveness of these immune-based modalities has encouraged interest in vaccine therapies for leukemia.
J N, Kochenderfer, J J, Molldrem
openaire +2 more sources
Leukemia is susceptible to immune-mediated therapies such as allogeneic stem-cell transplantation, donor lymphocyte infusion, and interferon. The clinical effectiveness of these immune-based modalities has encouraged interest in vaccine therapies for leukemia.
J N, Kochenderfer, J J, Molldrem
openaire +2 more sources
2020
Leukemia is a malignant clonal disease that originates from hematopoietic stem cells. As in-depth research examines the molecular biology and immunology of the hematopoietic system, leukemia treatment has evolved from a single cytotoxic drug to treatments that inducing differentiation and apoptosis.
Zhong, Zheng +4 more
openaire +2 more sources
Leukemia is a malignant clonal disease that originates from hematopoietic stem cells. As in-depth research examines the molecular biology and immunology of the hematopoietic system, leukemia treatment has evolved from a single cytotoxic drug to treatments that inducing differentiation and apoptosis.
Zhong, Zheng +4 more
openaire +2 more sources
Dermatologic Clinics, 1994
Leukemia cutis is an uncommon manifestation of leukemia that is strongly associated with the presence of extramedullary disease at other sites. Patients usually present with leukemia cutis concomitantly with systemic leukemia or after leukemia has been diagnosed.
K V, Ratnam, C J, Khor, W P, Su
openaire +2 more sources
Leukemia cutis is an uncommon manifestation of leukemia that is strongly associated with the presence of extramedullary disease at other sites. Patients usually present with leukemia cutis concomitantly with systemic leukemia or after leukemia has been diagnosed.
K V, Ratnam, C J, Khor, W P, Su
openaire +2 more sources
Current Treatment Options in Oncology, 2005
Prolymphocytic leukemia is a rare chronic lymphoproliferative disorder that includes two subtypes, B cell and T cell, each with its own distinct clinical, laboratory and pathological features. T-cell prolymphocytic leukemia has an aggressive course with short median survival and poor response to chemotherapy.
Ahmed, Absi, Eric, Hsi, Matt, Kalaycio
openaire +2 more sources
Prolymphocytic leukemia is a rare chronic lymphoproliferative disorder that includes two subtypes, B cell and T cell, each with its own distinct clinical, laboratory and pathological features. T-cell prolymphocytic leukemia has an aggressive course with short median survival and poor response to chemotherapy.
Ahmed, Absi, Eric, Hsi, Matt, Kalaycio
openaire +2 more sources
Expert Review of Hematology, 2010
Clofarabine is a second-generation purine nucleoside analogue that has been synthesized to overcome the limitations and incorporate the best qualities of fludarabine and cladribine. Clofarabine acts by inhibiting ribonucleotide reductase and DNA polymerase, thereby depleting the amount of intracellular deoxynucleoside triphosphates available for DNA ...
Hady, Ghanem +5 more
openaire +2 more sources
Clofarabine is a second-generation purine nucleoside analogue that has been synthesized to overcome the limitations and incorporate the best qualities of fludarabine and cladribine. Clofarabine acts by inhibiting ribonucleotide reductase and DNA polymerase, thereby depleting the amount of intracellular deoxynucleoside triphosphates available for DNA ...
Hady, Ghanem +5 more
openaire +2 more sources
Myelodysplasia and the leukemias
Current Problems in Cancer, 1997The armistice after World War II marked the beginning of an era that was to last to the end of the present century. It was an era in which many changes in medicine and nursing combined to alter the entire philosophy of managing malignant disease. More specifically, the fluid-phase tumors, which comprise myelodysplasia and the leukemias, were singled ...
openaire +2 more sources
Pediatrics, 1972
I read with interest the report1 by Drs. Jaffe and Kim regarding hypoglycemia in a child with acute myelogenous leukemia. I should like to call to your attention our reports2,3 describing reduced liver-glucose-6-phosphatase in children with leukemia.
openaire +2 more sources
I read with interest the report1 by Drs. Jaffe and Kim regarding hypoglycemia in a child with acute myelogenous leukemia. I should like to call to your attention our reports2,3 describing reduced liver-glucose-6-phosphatase in children with leukemia.
openaire +2 more sources